Composition of R&D Committee as of 15 June 2010
(Thomson Reuters ONE) -
ORION CORPORATION STOCK EXCHANGE RELEASE 15 June 2010 AT 01.55 EET
The Board of Directors of Orion Corporation has decided to complement the
composition of the R&D Committee with Matti Kavetvuo and Heikki Westerlund as
new members as of 15 June 2010. Accordingly, all members of the Board of
Directors belong to the R&D Committee.
Composition of the R&D Committee as of 15 June 2010:
Sirpa Jalkanen (Chairman)
Eero Karvonen
Matti Kavetvuo
Hannu Syrjänen
Heikki Westerlund
Jukka Ylppö
Orion Corporation
Timo Lappalainen Olli Huotari
President and CEO SVP, Corporate Functions
Contact person:
Olli Huotari, SVP, Corporate Functions, phone +358 50 966 3054
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
Homepage: www.orion.fi
Orion is an innovative European R&D-based pharmaceutical and diagnostic company
with a special emphasis on developing medicinal treatments and diagnostic tests
for global markets. Orion develops, manufactures and markets human and
veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic
tests. Orion's pharmaceutical R&D focuses on the following core therapy areas:
central nervous system drugs, cancer and critical care drugs, and Easyhaler(®)
pulmonary drugs.
The Group's net sales in 2009 amounted to EUR 772 million. The Company invested
EUR 95 million in research and development. At the end of 2009, the Group had a
total of 3,100 employees, of whom 2,500 worked in Finland and 600 in other
European countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.
[HUG#1424015]
Unternehmensinformation / Kurzprofil:
Datum: 15.06.2010 - 12:56 Uhr
Sprache: Deutsch
News-ID 22454
Anzahl Zeichen: 0
contact information:
Town:
Espoo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 207 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Composition of R&D Committee as of 15 June 2010"
steht unter der journalistisch-redaktionellen Verantwortung von
Orion Oyj (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
